Business Context and Reporting Period
This Form 8-K was filed by Priveterra Acquisition Corp. on June 26, 2023, regarding its proposed business combination with AEON Biopharma, Inc. The filing reports developments related to the special stockholder meeting and supplements the definitive proxy statement filed May 12, 2023.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial metrics. It is limited to meeting-administration and proxy-solicitation matters.
Material Changes Versus the Prior Comparable Period
- The special meeting originally scheduled for June 26, 2023, was adjourned to June 28, 2023, at 12:00 p.m. Eastern Time.
- The meeting will be conducted virtually through the specified webcast website.
- The company supplemented its definitive proxy statement with information concerning the adjournment.
- The filing states that the meeting location, record date, redemption deadline, and other proposals were unchanged.
Guidance, Outlook, Risks, and Unusual Items
- Stockholders who previously submitted proxies and do not wish to change their votes need not take further action.
- Stockholders of record as of April 11, 2023, remained eligible to vote even if they subsequently sold their shares.
- Stockholders seeking to withdraw redemption requests could do so before the rescheduled meeting by requesting that the transfer agent return the shares.
- The filing contains customary forward-looking statement warnings concerning the proposed transaction, future performance, and pro forma information.
- Completion of the business combination remains subject to stockholder approval and other applicable conditions; the filing does not state the outcome of the vote.
Most Important Facts to Verify
- Whether stockholders approved the Business Combination Proposal at the adjourned June 28, 2023 meeting.
- The final number of shares redeemed and the resulting cash available to the combined company.
- Whether all other closing conditions for the AEON Biopharma transaction were satisfied.
- The transaction’s final ownership structure, financing, valuation, and expected closing date, which are not provided in this filing.
- Subsequent SEC filings for the meeting results, transaction closing, and any updated financial information.